Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    NCT01244191
Show Display Options
Rank Status Study
1 Active, not recruiting ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer
Condition: Non Squamous, Non-small-cell Lung Cancer
Interventions: Drug: Tivantinib (ARQ 197) plus erlotinib;   Drug: ARQ 197 placebo plus erlotinib

Indicates status has not been verified in more than two years